Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Volunteers
This study aims to evaluate how the drug AZD0780 affects the body's processing of metformin in healthy volunteers.
AZD0780
+ Metformin
Metabolic Diseases+1
+ Nutritional and Metabolic Diseases
+ Dyslipidemias
Treatment Study
Summary
Study start date: November 10, 2025
Actual date on which the first participant was enrolled.This clinical trial aims to study how the drug AZD0780 affects the way the body processes another medication called metformin, which is commonly used to manage blood sugar levels. The study involves healthy male and female participants to understand potential interactions between these two drugs. This research is important because it can provide valuable information about whether AZD0780 changes how metformin works, which could influence future treatments involving these medications. Participants in this study will go through a screening process lasting up to 28 days to ensure they are suitable for the trial. Then, they will spend time living at the clinical unit during two treatment periods, where they will first receive metformin alone and then in combination with AZD0780. The study will observe how the body absorbs, distributes, and eliminates metformin in both scenarios. This trial will help determine if there are any significant changes in the drug's behavior when taken with AZD0780, without specifically mentioning risks or benefits.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.14 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 55 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Have a body mass index (BMI) between 18 and 35 kilograms per meter squared (kg/m2) inclusive and weigh at least 50 kilograms (kg) at the Screening Visit. * Participants agree to follow study specific contraceptive requirements. * Have suitable veins for cannulation or repeated venipuncture. Exclusion Criteria: * History of any clinically important disease or disorder which may put the participant at risk because of participation in the study or influence the results. * Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV). * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to metformin or AZD0780. * Treatment with any lipid lowering therapy or AZD0780 within the 3 months prior to the Screening Visit. * Treatment with drugs for reduction or inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) within the last 12 months prior to the Screening Visit (approved or investigational and apart from AZD0780). * Current or previous administration of inclisiran.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location